Stocks making the biggest moves midday: Lennar, Capri, Vicor, Amgen & more
Lennar rose 4% after Berkshire Hathaway bought 2.7M shares. Amgen gained 3% on positive trial results. Grab Holdings jumped 7% after CEO's share purchase. Capri rose 7% amid potential buyout talks. Shopify gained 7% with Meta AI integration. Quest Diagnostics and Labcorp dropped 5.3% and 3.6% on Medicare payment changes. Vicor rallied 14% on strong Q3 guidance. On Holding jumped 10% on new financial targets. GameStop gained 4% after CEO's share purchase.
How this was made
The 30-second read
Why it matters
Multiple companies experienced significant intraday moves driven by fresh corporate disclosures, insider activity, and regulatory news.
Market read
The article provides actionable insight into several stocks with fresh catalysts, useful for short-term traders.
What to watch
Regulatory risks for biotech trial, macro payment reforms for diagnostics, and AI integration challenges.
Background
Midday market roundup highlighting the biggest price movers and their catalysts.
Ticker impact
Lennar rose >4% after Berkshire Hathaway disclosed purchase of >2.7M shares.
Further upside if Berkshire adds more shares.
Large institutional buy often precedes price rally.
Capri Holdings up 7% after reports of buyer interest.
Short-term rally; watch for acquisition announcement.
Buyer talks can trigger speculative buying.
Amgen gained >3% on positive Phase 3 trial results for dazodalibep.
Potential upside if data leads to FDA filing.
Phase 3 success is material for biotech valuation.
Grab shares jumped >7% after CEO bought 10.4M shares.
Likely short-term rally; monitor further insider activity.
Large insider purchase can move sentiment.
SoFi up >1% after stablecoin settlement launched on its cards.
Modest upside as crypto adoption grows.
Incremental product launch, limited immediate impact.
Shopify shares up ~7% after announcing use of Meta's Muse AI for checkout.
Potential upside if AI improves merchant metrics.
AI rollout is a growth catalyst but execution risk remains.
Quest Diagnostics fell 5.3% after CMS report on Medicare overpaying labs.
Downside pressure if reimbursement rates fall.
Policy change directly affects revenue.
Labcorp dropped 3.6% after same CMS payment report.
Potential further decline if Medicare rates adjust.
Sector-wide reimbursement issue.
Market effects
Homebuilding, biotech, fintech, AI, and power electronics sectors see heightened attention.
US equities dominate; Asian markets watch Grab and On developments.
Broad impact across multiple industries due to simultaneous price moves.
Counterpoint
Some moves may be short-lived speculation; fundamentals may not support sustained gains.
Key entities
- InvestorBerkshire Hathaway
Increased stake in Lennar.
- RegulatorCMS
Released Medicare payment alignment report.
